Petrus Trust Company LTA Has $241,000 Holdings in LivaNova PLC $LIVN

Key Points

• Petrus Trust Company LTA reduced its stake in LivaNova PLC by 55.9% in Q1, now holding 6,140 shares valued at $241,000.
• Other institutional investors like GAMMA Investing LLC and Two Sigma Advisers LP have significantly increased their holdings in LivaNova, indicating strong interest in the stock.
• Analysts have set a consensus rating of "Buy" for LivaNova, with a price target averaging $59.71, following several positive upgrades over recent months.

Petrus Trust Company LTA cut its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 55.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,140 shares of the company's stock after selling 7,789 shares during the quarter. Petrus Trust Company LTA's holdings in LivaNova were worth $241,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company's stock valued at $1,394,000 after acquiring an additional 1,360 shares in the last quarter. AQR Capital Management LLC lifted its position in LivaNova by 111.7% in the 1st quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock valued at $60,809,000 after acquiring an additional 829,115 shares in the last quarter. Amundi raised its stake in LivaNova by 7.2% during the 1st quarter. Amundi now owns 196,435 shares of the company's stock valued at $7,362,000 after buying an additional 13,142 shares during the last quarter. Dark Forest Capital Management LP raised its stake in LivaNova by 960.1% during the 1st quarter. Dark Forest Capital Management LP now owns 275,054 shares of the company's stock valued at $10,804,000 after buying an additional 249,107 shares during the last quarter. Finally, EP Wealth Advisors LLC purchased a new stake in shares of LivaNova in the 1st quarter worth $293,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Barclays increased their price target on LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a report on Tuesday, May 20th. Needham & Company LLC reissued a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research report on Wednesday, September 3rd. Finally, Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $59.71.

LivaNova Stock Down 2.0%

LIVN stock traded down $1.12 during midday trading on Friday, hitting $56.22. The company's stock had a trading volume of 571,347 shares, compared to its average volume of 563,145. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $58.91. The firm has a 50-day simple moving average of $49.83 and a 200-day simple moving average of $44.05. The firm has a market capitalization of $3.07 billion, a P/E ratio of -14.45 and a beta of 0.97. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. During the same period last year, the business posted $0.93 EPS. The company's revenue was up 10.6% on a year-over-year basis. As a group, equities analysts forecast that LivaNova PLC will post 2.85 EPS for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.